Effect of Concord Grape Juice on Endothelial Function

Sponsor
Boston University (Other)
Overall Status
Completed
CT.gov ID
NCT01775748
Collaborator
Welch's, Inc. (Industry)
77
1
2
14.5
5.3

Study Details

Study Description

Brief Summary

The study will compare Concord grape juice to a beverage that contains no grape flavonoids, but has a similar appearance and taste (placebo juice). A total of 60 overweight and obese participants over age 50 will be enrolled. Each participant will drink each beverage for 4 weeks with a 2-week rest period between two beverage consumption periods. The order of beverages (grape juice first or placebo juice first) will be randomized. The investigators will use ultrasound to measure brachial artery flow-mediated dilation, a measure of endothelial vasodilator function. The investigators will also collect blood samples to further assess the cardiovascular effects of grape juice.

The aim of the study is to determine whether Concord grape juice improves endothelial function in patients at risk who do not have cardiovascular disease and may provide information that would guide dietary recommendations. The results may also be used by the sponsor to substantiate claims and labeling of their product.

Condition or Disease Intervention/Treatment Phase
  • Other: Active Concord Grape Juice 12 oz per day
  • Other: Placebo Grape Juice 12 oz per day
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
77 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Other
Official Title:
Effect Of Concord Grape Juice On Endothelial Function In Obese And Overweight Individuals Over Age 50
Actual Study Start Date :
Jan 1, 2013
Actual Primary Completion Date :
Mar 19, 2014
Actual Study Completion Date :
Mar 19, 2014

Arms and Interventions

Arm Intervention/Treatment
Other: Active First

Active Concord Grape Juice 12 oz per day Placebo Grape Juice 12 oz per day

Other: Active Concord Grape Juice 12 oz per day
Grape Juice 12 oz per day

Other: Placebo Grape Juice 12 oz per day
Placebo Grape Juice 12 oz per day

Other: Placebo First

Placebo Grape Juice 12 oz per day Active Concord Grape Juice 12 oz per day

Other: Active Concord Grape Juice 12 oz per day
Grape Juice 12 oz per day

Other: Placebo Grape Juice 12 oz per day
Placebo Grape Juice 12 oz per day

Outcome Measures

Primary Outcome Measures

  1. Brachial artery flow mediated dilation [4 weeks]

    Endothelial function will be assessed as brachial artery flow-mediated dilation using vascular ultrasound

Secondary Outcome Measures

  1. Nitroglycerin-mediated dilation [4 weeks]

    Non-endothelium-dependent dilation will be assessed by measuring the dilator response to sublingual nitroglycerin using vascular ultrasound

  2. Carotid-Femoral Pulse Wave Velocity [4 weeks]

    Central aortic stiffness will be assessed as carotid-femoral pulse wave velocity using applanation tonometry

  3. Reactive hyperemia [4 weeks]

    We will use vascular ultrasound to determine maximal hyperemic flow velocity in the brachial artery induced by 4-minute cuff occlusion.

Other Outcome Measures

  1. Fasting glucose and insulin [4 weeks]

    Fasting glucose and insulin

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Body mass index ≥ 25 and < 40 kg/m2

  • Age ≥ 50 years

  • Otherwise healthy

Exclusion Criteria:
  • Clinical diagnosis of atherosclerotic vascular disease.

  • Clinical history of diabetes mellitus or fasting glucose ≥126 mg/dl

  • Uncontrolled hypertension

  • Treatment with an investigational new drug within the last 30 days

  • Clinical history of other major illness including end-stage cancer, renal failure, hepatic failure, or other conditions that in the opinion of the principal investigator make the study inappropriate

  • Psychological illness or condition such as to interfere with the subject's ability to understand the requirements of the study

  • Use of Vitamin E, Vitamin C, beta carotene, lipoic acid, or other food or herbal supplements within 1 month of enrollment. Subjects taking multivitamins or other forms of vitamin E and C in doses that do not exceed two times the recommended daily allowance will not be excluded

  • Extreme dietary habits (i.e. Atkins, very high protein/low carbohydrate, or vegan diet

Contacts and Locations

Locations

Site City State Country Postal Code
1 Boston University School of Medicine Boston Massachusetts United States 02118

Sponsors and Collaborators

  • Boston University
  • Welch's, Inc.

Investigators

  • Principal Investigator: Robert E Eberhardt, MD, Boston University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Boston University
ClinicalTrials.gov Identifier:
NCT01775748
Other Study ID Numbers:
  • H-31937
First Posted:
Jan 25, 2013
Last Update Posted:
Feb 12, 2018
Last Verified:
Feb 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Boston University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 12, 2018